Incyte Corp. (INCY)

Company Description

Incyte Corporation (Wilmington, Delaware) is a biopharmaceutical company that is focused on developing novel small molecule therapies for the treatments of cancers and inflammatory diseases. The company obtained approval in the U.S. for Jakafi in late 2011, which is a first-in class compound for myeloproliferative disorders that inhibits the intraceullar Janus kinases (Jak) signaling pathway; the ex-U.S. ruxolitinib rights have been licensed to Novartis in a deal potentially valued at up to $1 billion. INCY’s second key pipeline product is INCB28050, which is a second-generation oral Jak inhibitor in development for autoimmune disorders such as rheumatoid arthritis. The company has licensed global rights to INCB28050 to Lilly, and plans to co-develop the agent in rheumatoid arthritis. Behind ruxolitinib and INCB28050, INCY has several earlierstage Phase I/II oncology assets, which have different mechanisms of action, and a fully owned second generation Jakafi.


Route 141 & Henry Clay Road
Wilmington, DE 19880
United States



Get BioInvest's perspective on Incyte's CEO

Latest Company News

Equity in Focus: Incyte Corporation (NASDAQ:INCY) Baldwin Journal - 16 hours ago Investors may be checking on some financial ratios for Incyte Corporation (NASDAQ:INCY). Currently, the company has a Gross Margin (Marx) ratio of 0.284189. Top Gainers of the Day: Incyte Corporation (NASDAQ:INCY) from Biotechnology - Twin County News [...]
Thu, Apr 27, 2017 1:41:00 PM, Continue reading at the source
Should You Get Rid of Incyte Corporation (INCY) Now? Yahoo Finance - Apr 26, 2017 One such stock that you may want to consider dropping is Incyte Corporation INCY, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Incyte Corporation (INCY): Ignore the noise and focus on the technicals - USA Commerce Daily [...]
Wed, Apr 26, 2017 1:30:00 PM, Continue reading at the source
Why Investors remained buoyant on: Fortinet, Inc. (FTNT), Incyte Corporation ... StockNewsJournal - Apr 24, 2017 Fortinet, Inc. (NASDAQ:FTNT) market capitalization at present is $6.92B at the rate of $39.53 a share. The firm's price-to-sales ratio was noted 5.43 in contrast with an overall industry average of 4.40. [...]
Mon, Apr 24, 2017 2:31:00 PM, Continue reading at the source
Incyte: Little Upside Left Seeking Alpha - Apr 24, 2017 DCF Analysis shows Incyte is undervalued by only between 2% (Perpetuity Growth Method) and 0% (EBITDA Multiple Method). Under a worst-case scenario, Incyte is overvalued by approximately 59% (Perpetuity Growth Method) and 62% (EBITDA Multiple ... [...]
Mon, Apr 24, 2017 12:11:00 PM, Continue reading at the source
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ... PR Newswire (press release) - Apr 20, 2017 NEW YORK, April 20, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors are ... SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ... - [...]
Thu, Apr 20, 2017 2:19:00 PM, Continue reading at the source
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ... PR Newswire (press release) - Apr 19, 2017 NEW YORK, April 19, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors are advised to contact Robert S. Willoughby at ... [...]
Wed, Apr 19, 2017 3:33:00 PM, Continue reading at the source
Why Dish Network Corp (DISH), Snyder's-Lance Inc (LNCE) and Incyte Corporation ... - Apr 17, 2017 While stocks may have ended last week's holiday-shortened trading on a low note, the three-day weekend gave traders a chance to forget about their concerns and get back on their bullish horse. Incyte Corporation (INCY) Stock: Takes A Dive As FDA Fails To Approve Treatment - CNA Finance (press release) [...]
Mon, Apr 17, 2017 9:00:00 PM, Continue reading at the source
Why Incyte Corporation Stock Is Plunging Today Motley Fool - Apr 17, 2017 Shares of Incyte Corporation (NASDAQ:INCY) fell by as much as 11.9% on Monday as a result of the FDA rejecting its once-daily rheumatoid arthritis pill, baricitinib, for safety and dosing reasons. Incyte: Buy On The Drop? - Seeking Alpha Incyte Corporation (INCY) Shares Tumble on FDA Setback for Rheumatoid ... - Smarter Analyst [...]
Mon, Apr 17, 2017 4:47:00 PM, Continue reading at the source
Incyte Dramatically Ups The Immuno-Oncology Combo Ante Seeking Alpha - Apr 3, 2017 Incyte (NASDAQ:INCY) has propelled itself into the immuno-oncology premier league by revealing plans to initiate eight new phase III studies with its IDO1 inhibitor epacadostat and an anti-PD-1 antibody, bringing the total of such registration trials ... Incyte Corporation (INCY) Likely Looking to Assess Epacadostat + Opdivo in ... - Smаrt Stоck Nеws Leading Indus Mover Under Analysts Crush: Assured Guaranty (AGO), Incyte ... - Seneca Globe [...]
Mon, Apr 03, 2017 6:22:00 PM, Continue reading at the source
Incyte Corporation Risk Points versus Health Care CML News - Mar 30, 2017 This is a scatter plot analysis of the critical risk points from the option market for Incyte Corporation (NASDAQ:INCY) compared to its own past and the Health Care ETF. [...]
Thu, Mar 30, 2017 11:25:00 AM, Continue reading at the source